Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Chimeric Therapeutics Ltd

CHM.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.00

▲ +0.00%

Market Cap $309.49K · Vol 25.13M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$309.49K

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

1.10

vs Market

52W High

$0.28

99.22% below

52W Low

$0.00

0.00% above

Volume

25.13M

Avg 1.48M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

84.99%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Chimeric Therapeutics Ltd (CHM.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CHM.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-92.86%

-98.18%

YTD

-98.50%

-99.00%

-99.88%

-99.99%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,014,260.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-164.44% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	147.46M

Technical Indicators

50-Day SMA	$0.00
200-Day SMA	$0.07
RSI (14)	50.00
Beta	1.10
52-Week High	$0.28
52-Week Low	$0.00

Volume Today	25.13M
Avg Daily Volume (30D)	1.48M
Relative Volume	17.00x
Volatility (10D)	0.00
Volatility (30D)	199.45
Free Float	84.99%

Analyst Consensus

N/A

Current Price $0.00

Mean Target N/A

52W Low$0.00 52W High$0.28

Current

Target

$0.00 $0.28

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00YD0SSP1

ISINAU0000121576

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.22% ARGX.BR argenx SE -2.87% ARGX argenx SE -2.00% GMAB.CO Genmab A/S -5.47% GMAB Genmab A/S -3.75%

Company Profile

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.